Fulcrum Therapeutics, Inc. (FULC) 10-Year Financial Performance & Capital Metrics

FULC • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutFulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $80M +2752.0%
EBITDA -$20M +81.3%
Net Income -$10M +90.0%
EPS (Diluted) -0.16 +89.9%
Gross Margin 20.77% -79.2%
EBITDA Margin -25.38% +99.3%
Operating Margin -27.37% +99.3%
Net Margin -12.16% +99.6%
ROE -4.07% +90.9%
ROIC -7.94% +81.0%
Debt/Equity 0.04 -22.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 82 (top 18%)

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y61.02%

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-297%

EPS CAGR

10Y-

5Y-

3Y-

TTM-280.65%

ROCE

10Y Avg-232.13%

5Y Avg-46.51%

3Y Avg-36.83%

Latest-8.87%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	8.82M	19.16M	6.34M	2.81M	80M
Revenue Growth %	-	-	-	-	1.17%	-0.67%	-0.56%	27.52%
Cost of Goods Sold+	715K	1.34M	2.05M	59.04M	69.7M	76.78M	0	63.39M
COGS % of Revenue	-	-	-	6.69%	3.64%	12.11%	-	0.79%
Gross Profit+	-715K	-1.34M	-2.05M	-50.22M	-50.54M	-70.44M	2.81M	16.61M
Gross Margin %	-	-	-	-5.69%	-2.64%	-11.11%	1%	0.21%
Gross Profit Growth %	-	-0.88%	-0.53%	-23.46%	-0.01%	-0.39%	1.04%	4.92%
Operating Expenses+	22.99M	33.5M	56.57M	21.39M	30.52M	42.12M	113.47M	38.51M
OpEx % of Revenue	-	-	-	2.42%	1.59%	6.64%	40.45%	0.48%
Selling, General & Admin	4.5M	8.31M	13.14M	21.39M	30.52M	41.69M	41.67M	36.45M
SG&A % of Revenue	-	-	-	2.42%	1.59%	6.57%	14.85%	0.46%
Research & Development	18.49M	25.18M	43.43M	59.04M	69.7M	76.78M	71.8M	63.39M
R&D % of Revenue	-	-	-	6.69%	3.64%	12.11%	25.6%	0.79%
Other Operating Expenses	28K	392K	0	-59.04M	-69.7M	-76.36M	0	-61.32M
Operating Income+	-22.99M	-33.5M	-58.63M	-71.61M	-81.05M	-112.56M	-110.66M	-21.9M
Operating Margin %	-	-	-	-8.12%	-4.23%	-17.75%	-39.45%	-0.27%
Operating Income Growth %	-	-0.46%	-0.75%	-0.22%	-0.13%	-0.39%	0.02%	0.8%
EBITDA+	-22.28M	-32.15M	-56.57M	-69.23M	-78.54M	-110.15M	-108.49M	-20.3M
EBITDA Margin %	-	-	-	-7.85%	-4.1%	-17.37%	-38.68%	-0.25%
EBITDA Growth %	-	-0.44%	-0.76%	-0.22%	-0.13%	-0.4%	0.02%	0.81%
D&A (Non-Cash Add-back)	715K	1.34M	2.05M	2.38M	2.52M	2.41M	2.17M	1.59M
EBIT	-22.99M	-33.5M	-82.68M	-71.61M	-81.05M	-112.13M	-110.66M	-19.83M
Net Interest Income+	0	0	1.51M	792K	207K	0	0	0
Interest Income	0	0	1.51M	792K	207K	0	0	0
Interest Expense	0	0	0	0	0	0	0	0
Other Income/Expense	29K	910K	-24.05M	792K	207K	2.69M	13.33M	12.17M
Pretax Income+	-22.96M	-32.59M	-82.68M	-70.82M	-80.85M	-109.87M	-97.33M	-9.72M
Pretax Margin %	-	-	-	-8.03%	-4.22%	-17.32%	-34.7%	-0.12%
Income Tax+	-1K	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-22.96M	-32.59M	-82.68M	-70.82M	-80.85M	-109.87M	-97.33M	-9.72M
Net Margin %	-	-	-	-8.03%	-4.22%	-17.32%	-34.7%	-0.12%
Net Income Growth %	-	-0.42%	-1.54%	0.14%	-0.14%	-0.36%	0.11%	0.9%
Net Income (Continuing)	-22.96M	-32.59M	-82.68M	-70.82M	-80.85M	-109.87M	-97.33M	-9.72M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.36	-1.92	-3.49	-2.70	-2.22	-2.35	-1.59	-0.16
EPS Growth %	-	-0.41%	-0.82%	0.23%	0.18%	-0.06%	0.32%	0.9%
EPS (Basic)	-1.36	-1.92	-3.49	-2.70	-2.22	-2.35	-1.59	-0.16
Diluted Shares Outstanding	16.94M	16.94M	22.66M	25.35M	35.36M	44.99M	61.31M	61.98M
Basic Shares Outstanding	16.94M	16.94M	22.66M	25.35M	35.36M	44.99M	61.31M	61.98M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.34M	74.09M	100.08M	112.91M	226M	207.52M	242.2M	249.92M
Cash & Short-Term Investments	407K	72.8M	96.71M	112.91M	218.16M	202.92M	236.22M	241.02M
Cash Only	407K	72.8M	96.71M	57.05M	35.41M	35.1M	25.56M	58.21M
Short-Term Investments	0	0	0	55.86M	182.75M	167.82M	210.66M	182.81M
Accounts Receivable	39K	501K	111K	2.71M	4.11M	1.08M	2.25M	3.34M
Days Sales Outstanding	-	-	-	111.99	78.28	62.21	292.65	15.25
Inventory	734K	559K	2.98M	-2.78M	-473K	0	0	0
Days Inventory Outstanding	374.7	151.7	528.92	-	-	-	-	-
Other Current Assets	248K	238K	284K	74K	0	0	0	0
Total Non-Current Assets+	3M	11.68M	10.36M	16.66M	9M	19.17M	15.49M	10.79M
Property, Plant & Equipment	2.94M	10.55M	87.94M	8.4M	7.37M	15.97M	12.39M	9.58M
Fixed Asset Turnover	-	-	-	1.05x	2.60x	0.40x	0.23x	8.35x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	1.09M	1.09M	1.09M	1.09M	1.09M	0	0
Other Non-Current Assets	60K	38K	-78.68M	7.17M	542K	2.1M	3.1M	1.21M
Total Assets+	4.34M	85.77M	110.44M	129.58M	235M	226.69M	257.69M	260.72M
Asset Turnover	-	-	-	0.07x	0.08x	0.03x	0.01x	0.31x
Asset Growth %	-	18.76%	0.29%	0.17%	0.81%	-0.04%	0.14%	0.01%
Total Current Liabilities+	2.79M	4.23M	12.14M	26.73M	19.2M	16.73M	13.68M	11.04M
Accounts Payable	1.67M	1.26M	2.19M	4.08M	4.79M	3.64M	2.76M	1.16M
Days Payables Outstanding	854.05	342.75	388.65	25.22	25.07	17.29	-	6.7
Short-Term Debt	0	0	0	0	0	2.6M	0	0
Deferred Revenue (Current)	0	1000K	1000K	1000K	1000K	934K	0	0
Other Current Liabilities	20K	781K	3.68M	4.79M	4.71M	5.34M	396K	463K
Current Ratio	0.48x	17.52x	8.24x	4.23x	11.77x	12.41x	17.71x	22.63x
Quick Ratio	0.22x	17.39x	8.00x	4.33x	11.80x	12.41x	17.71x	22.63x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	233K	5.54M	11.15M	7.67M	4.26M	11.02M	8.83M	6.64M
Long-Term Debt	34.59M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	10.82M	8.63M	6.44M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	-34.35M	5.54M	5.13M	4.7M	4.26M	0	197K	197K
Total Liabilities	3.02M	9.77M	23.29M	34.4M	23.46M	27.74M	22.5M	17.68M
Total Debt+	34.59M	46K	50K	17K	0	13.42M	10.82M	8.63M
Net Debt	34.18M	-72.75M	-96.66M	-57.03M	-35.41M	-21.68M	-14.74M	-49.58M
Debt / Equity	26.16x	0.00x	0.00x	0.00x	-	0.07x	0.05x	0.04x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-
Total Equity+	1.32M	76M	87.15M	95.18M	211.54M	198.94M	235.19M	243.03M
Equity Growth %	-	56.49%	0.15%	0.09%	1.22%	-0.06%	0.18%	0.03%
Book Value per Share	0.08	4.49	3.85	3.75	5.98	4.42	3.84	3.92
Total Shareholders' Equity	1.32M	76M	87.15M	95.18M	211.54M	198.94M	235.19M	243.03M
Common Stock	1K	16K	23K	28K	41K	52K	62K	54K
Retained Earnings	-35.54M	-68.12M	-150.8M	-221.62M	-302.47M	-412.34M	-509.67M	-519.4M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-893K	-1.96M	-110.44M	-2K	-397K	-797K	-136K	130K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.07M	-22.56M	-39.48M	-53.66M	-78.48M	-97.05M	-90.97M	-2.22M
Operating CF Margin %	-	-	-	-6.08%	-4.1%	-15.3%	-32.43%	-0.03%
Operating CF Growth %	-	-0.12%	-0.75%	-0.36%	-0.46%	-0.24%	0.06%	0.98%
Net Income	-22.96M	-32.59M	-82.68M	-70.82M	-80.85M	-109.87M	-97.33M	-9.72M
Depreciation & Amortization	715K	1.34M	2.05M	2.38M	2.52M	2.41M	2.17M	1.59M
Stock-Based Compensation	1.37M	2.16M	4.22M	7.35M	11.07M	13.35M	14.8M	14.55M
Deferred Taxes	0	0	0	1.93M	0	0	0	0
Other Non-Cash Items	2.59M	4.87M	25.59M	-2M	673K	152K	-5.99M	-4.39M
Working Capital Changes	804K	6.52M	11.33M	7.5M	-11.89M	-3.09M	-4.61M	-4.25M
Change in Receivables	0	0	0	-2M	-500K	2.5M	-308K	-1.56M
Change in Inventory	0	0	0	229K	1.25M	0	0	0
Change in Payables	208K	-20K	803K	1.77M	973K	-1.18M	-853K	-1.59M
Cash from Investing+	-1.91M	-8.98M	-944K	-57.14M	-129.67M	12.41M	-36.69M	32.23M
Capital Expenditures	-1.91M	-8.98M	-853K	-1.34M	-1.71M	-1.96M	-508K	-278K
CapEx % of Revenue	-	-	-	0.15%	0.09%	0.31%	0.18%	0%
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	-91K	-55.8M	-127.96M	14.38M	0	0
Cash from Financing+	17.66M	105.03M	64.34M	71.13M	186.51M	84.32M	118.12M	2.75M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	17.66M	12K	249K	1.24M	3.67M	3.52M	777K	0
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-21.98M	-31.54M	-40.34M	-55M	-80.19M	-99.01M	-91.47M	-2.5M
FCF Margin %	-	-	-	-6.23%	-4.18%	-15.61%	-32.61%	-0.03%
FCF Growth %	-	-0.43%	-0.28%	-0.36%	-0.46%	-0.23%	0.08%	0.97%
FCF per Share	-1.30	-1.86	-1.78	-2.17	-2.27	-2.20	-1.49	-0.04
FCF Conversion (FCF/Net Income)	0.87x	0.69x	0.48x	0.76x	0.97x	0.88x	0.93x	0.23x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-1737.07%	-84.29%	-101.35%	-77.68%	-52.72%	-53.53%	-44.84%	-4.07%
Return on Invested Capital (ROIC)	-48.57%	-129.67%	-	-375.11%	-56.74%	-47.78%	-41.74%	-7.94%
Gross Margin	-	-	-	-569.18%	-263.73%	-1110.69%	100%	20.77%
Net Margin	-	-	-	-802.66%	-421.89%	-1732.43%	-3470.05%	-12.16%
Debt / Equity	26.16x	0.00x	0.00x	0.00x	-	0.07x	0.05x	0.04x
FCF Conversion	0.87x	0.69x	0.48x	0.76x	0.97x	0.88x	0.93x	0.23x
Revenue Growth	-	-	-	-	117.19%	-66.91%	-55.77%	2752.05%

Frequently Asked Questions

Growth & Financials

Fulcrum Therapeutics, Inc. (FULC) reported $80.0M in revenue for fiscal year 2024.

Fulcrum Therapeutics, Inc. (FULC) grew revenue by 2752.0% over the past year. This is strong growth.

Fulcrum Therapeutics, Inc. (FULC) reported a net loss of $71.1M for fiscal year 2024.

Dividend & Returns

Fulcrum Therapeutics, Inc. (FULC) has a return on equity (ROE) of -4.1%. Negative ROE indicates the company is unprofitable.

Fulcrum Therapeutics, Inc. (FULC) had negative free cash flow of $60.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Fulcrum Therapeutics, Inc. (FULC) 10-Year Financial Performance & Capital Metrics

FULC • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $80M +2752.0%
EBITDA -$20M +81.3%
Net Income -$10M +90.0%
EPS (Diluted) -0.16 +89.9%
Gross Margin 20.77% -79.2%
EBITDA Margin -25.38% +99.3%
Operating Margin -27.37% +99.3%
Net Margin -12.16% +99.6%
ROE -4.07% +90.9%
ROIC -7.94% +81.0%
Debt/Equity 0.04 -22.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 82 (top 18%)

✗Weaknesses

✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y61.02%

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-297%

EPS CAGR

10Y-

5Y-

3Y-

TTM-280.65%

ROCE

10Y Avg-232.13%

5Y Avg-46.51%

3Y Avg-36.83%

Latest-8.87%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	8.82M	19.16M	6.34M	2.81M	80M
Revenue Growth %	-	-	-	-	1.17%	-0.67%	-0.56%	27.52%
Cost of Goods Sold+	715K	1.34M	2.05M	59.04M	69.7M	76.78M	0	63.39M
COGS % of Revenue	-	-	-	6.69%	3.64%	12.11%	-	0.79%
Gross Profit+	-715K	-1.34M	-2.05M	-50.22M	-50.54M	-70.44M	2.81M	16.61M
Gross Margin %	-	-	-	-5.69%	-2.64%	-11.11%	1%	0.21%
Gross Profit Growth %	-	-0.88%	-0.53%	-23.46%	-0.01%	-0.39%	1.04%	4.92%
Operating Expenses+	22.99M	33.5M	56.57M	21.39M	30.52M	42.12M	113.47M	38.51M
OpEx % of Revenue	-	-	-	2.42%	1.59%	6.64%	40.45%	0.48%
Selling, General & Admin	4.5M	8.31M	13.14M	21.39M	30.52M	41.69M	41.67M	36.45M
SG&A % of Revenue	-	-	-	2.42%	1.59%	6.57%	14.85%	0.46%
Research & Development	18.49M	25.18M	43.43M	59.04M	69.7M	76.78M	71.8M	63.39M
R&D % of Revenue	-	-	-	6.69%	3.64%	12.11%	25.6%	0.79%
Other Operating Expenses	28K	392K	0	-59.04M	-69.7M	-76.36M	0	-61.32M
Operating Income+	-22.99M	-33.5M	-58.63M	-71.61M	-81.05M	-112.56M	-110.66M	-21.9M
Operating Margin %	-	-	-	-8.12%	-4.23%	-17.75%	-39.45%	-0.27%
Operating Income Growth %	-	-0.46%	-0.75%	-0.22%	-0.13%	-0.39%	0.02%	0.8%
EBITDA+	-22.28M	-32.15M	-56.57M	-69.23M	-78.54M	-110.15M	-108.49M	-20.3M
EBITDA Margin %	-	-	-	-7.85%	-4.1%	-17.37%	-38.68%	-0.25%
EBITDA Growth %	-	-0.44%	-0.76%	-0.22%	-0.13%	-0.4%	0.02%	0.81%
D&A (Non-Cash Add-back)	715K	1.34M	2.05M	2.38M	2.52M	2.41M	2.17M	1.59M
EBIT	-22.99M	-33.5M	-82.68M	-71.61M	-81.05M	-112.13M	-110.66M	-19.83M
Net Interest Income+	0	0	1.51M	792K	207K	0	0	0
Interest Income	0	0	1.51M	792K	207K	0	0	0
Interest Expense	0	0	0	0	0	0	0	0
Other Income/Expense	29K	910K	-24.05M	792K	207K	2.69M	13.33M	12.17M
Pretax Income+	-22.96M	-32.59M	-82.68M	-70.82M	-80.85M	-109.87M	-97.33M	-9.72M
Pretax Margin %	-	-	-	-8.03%	-4.22%	-17.32%	-34.7%	-0.12%
Income Tax+	-1K	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-22.96M	-32.59M	-82.68M	-70.82M	-80.85M	-109.87M	-97.33M	-9.72M
Net Margin %	-	-	-	-8.03%	-4.22%	-17.32%	-34.7%	-0.12%
Net Income Growth %	-	-0.42%	-1.54%	0.14%	-0.14%	-0.36%	0.11%	0.9%
Net Income (Continuing)	-22.96M	-32.59M	-82.68M	-70.82M	-80.85M	-109.87M	-97.33M	-9.72M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.36	-1.92	-3.49	-2.70	-2.22	-2.35	-1.59	-0.16
EPS Growth %	-	-0.41%	-0.82%	0.23%	0.18%	-0.06%	0.32%	0.9%
EPS (Basic)	-1.36	-1.92	-3.49	-2.70	-2.22	-2.35	-1.59	-0.16
Diluted Shares Outstanding	16.94M	16.94M	22.66M	25.35M	35.36M	44.99M	61.31M	61.98M
Basic Shares Outstanding	16.94M	16.94M	22.66M	25.35M	35.36M	44.99M	61.31M	61.98M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.34M	74.09M	100.08M	112.91M	226M	207.52M	242.2M	249.92M
Cash & Short-Term Investments	407K	72.8M	96.71M	112.91M	218.16M	202.92M	236.22M	241.02M
Cash Only	407K	72.8M	96.71M	57.05M	35.41M	35.1M	25.56M	58.21M
Short-Term Investments	0	0	0	55.86M	182.75M	167.82M	210.66M	182.81M
Accounts Receivable	39K	501K	111K	2.71M	4.11M	1.08M	2.25M	3.34M
Days Sales Outstanding	-	-	-	111.99	78.28	62.21	292.65	15.25
Inventory	734K	559K	2.98M	-2.78M	-473K	0	0	0
Days Inventory Outstanding	374.7	151.7	528.92	-	-	-	-	-
Other Current Assets	248K	238K	284K	74K	0	0	0	0
Total Non-Current Assets+	3M	11.68M	10.36M	16.66M	9M	19.17M	15.49M	10.79M
Property, Plant & Equipment	2.94M	10.55M	87.94M	8.4M	7.37M	15.97M	12.39M	9.58M
Fixed Asset Turnover	-	-	-	1.05x	2.60x	0.40x	0.23x	8.35x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	1.09M	1.09M	1.09M	1.09M	1.09M	0	0
Other Non-Current Assets	60K	38K	-78.68M	7.17M	542K	2.1M	3.1M	1.21M
Total Assets+	4.34M	85.77M	110.44M	129.58M	235M	226.69M	257.69M	260.72M
Asset Turnover	-	-	-	0.07x	0.08x	0.03x	0.01x	0.31x
Asset Growth %	-	18.76%	0.29%	0.17%	0.81%	-0.04%	0.14%	0.01%
Total Current Liabilities+	2.79M	4.23M	12.14M	26.73M	19.2M	16.73M	13.68M	11.04M
Accounts Payable	1.67M	1.26M	2.19M	4.08M	4.79M	3.64M	2.76M	1.16M
Days Payables Outstanding	854.05	342.75	388.65	25.22	25.07	17.29	-	6.7
Short-Term Debt	0	0	0	0	0	2.6M	0	0
Deferred Revenue (Current)	0	1000K	1000K	1000K	1000K	934K	0	0
Other Current Liabilities	20K	781K	3.68M	4.79M	4.71M	5.34M	396K	463K
Current Ratio	0.48x	17.52x	8.24x	4.23x	11.77x	12.41x	17.71x	22.63x
Quick Ratio	0.22x	17.39x	8.00x	4.33x	11.80x	12.41x	17.71x	22.63x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	233K	5.54M	11.15M	7.67M	4.26M	11.02M	8.83M	6.64M
Long-Term Debt	34.59M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	10.82M	8.63M	6.44M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	-34.35M	5.54M	5.13M	4.7M	4.26M	0	197K	197K
Total Liabilities	3.02M	9.77M	23.29M	34.4M	23.46M	27.74M	22.5M	17.68M
Total Debt+	34.59M	46K	50K	17K	0	13.42M	10.82M	8.63M
Net Debt	34.18M	-72.75M	-96.66M	-57.03M	-35.41M	-21.68M	-14.74M	-49.58M
Debt / Equity	26.16x	0.00x	0.00x	0.00x	-	0.07x	0.05x	0.04x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-
Total Equity+	1.32M	76M	87.15M	95.18M	211.54M	198.94M	235.19M	243.03M
Equity Growth %	-	56.49%	0.15%	0.09%	1.22%	-0.06%	0.18%	0.03%
Book Value per Share	0.08	4.49	3.85	3.75	5.98	4.42	3.84	3.92
Total Shareholders' Equity	1.32M	76M	87.15M	95.18M	211.54M	198.94M	235.19M	243.03M
Common Stock	1K	16K	23K	28K	41K	52K	62K	54K
Retained Earnings	-35.54M	-68.12M	-150.8M	-221.62M	-302.47M	-412.34M	-509.67M	-519.4M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-893K	-1.96M	-110.44M	-2K	-397K	-797K	-136K	130K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.07M	-22.56M	-39.48M	-53.66M	-78.48M	-97.05M	-90.97M	-2.22M
Operating CF Margin %	-	-	-	-6.08%	-4.1%	-15.3%	-32.43%	-0.03%
Operating CF Growth %	-	-0.12%	-0.75%	-0.36%	-0.46%	-0.24%	0.06%	0.98%
Net Income	-22.96M	-32.59M	-82.68M	-70.82M	-80.85M	-109.87M	-97.33M	-9.72M
Depreciation & Amortization	715K	1.34M	2.05M	2.38M	2.52M	2.41M	2.17M	1.59M
Stock-Based Compensation	1.37M	2.16M	4.22M	7.35M	11.07M	13.35M	14.8M	14.55M
Deferred Taxes	0	0	0	1.93M	0	0	0	0
Other Non-Cash Items	2.59M	4.87M	25.59M	-2M	673K	152K	-5.99M	-4.39M
Working Capital Changes	804K	6.52M	11.33M	7.5M	-11.89M	-3.09M	-4.61M	-4.25M
Change in Receivables	0	0	0	-2M	-500K	2.5M	-308K	-1.56M
Change in Inventory	0	0	0	229K	1.25M	0	0	0
Change in Payables	208K	-20K	803K	1.77M	973K	-1.18M	-853K	-1.59M
Cash from Investing+	-1.91M	-8.98M	-944K	-57.14M	-129.67M	12.41M	-36.69M	32.23M
Capital Expenditures	-1.91M	-8.98M	-853K	-1.34M	-1.71M	-1.96M	-508K	-278K
CapEx % of Revenue	-	-	-	0.15%	0.09%	0.31%	0.18%	0%
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	-91K	-55.8M	-127.96M	14.38M	0	0
Cash from Financing+	17.66M	105.03M	64.34M	71.13M	186.51M	84.32M	118.12M	2.75M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	17.66M	12K	249K	1.24M	3.67M	3.52M	777K	0
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-21.98M	-31.54M	-40.34M	-55M	-80.19M	-99.01M	-91.47M	-2.5M
FCF Margin %	-	-	-	-6.23%	-4.18%	-15.61%	-32.61%	-0.03%
FCF Growth %	-	-0.43%	-0.28%	-0.36%	-0.46%	-0.23%	0.08%	0.97%
FCF per Share	-1.30	-1.86	-1.78	-2.17	-2.27	-2.20	-1.49	-0.04
FCF Conversion (FCF/Net Income)	0.87x	0.69x	0.48x	0.76x	0.97x	0.88x	0.93x	0.23x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-1737.07%	-84.29%	-101.35%	-77.68%	-52.72%	-53.53%	-44.84%	-4.07%
Return on Invested Capital (ROIC)	-48.57%	-129.67%	-	-375.11%	-56.74%	-47.78%	-41.74%	-7.94%
Gross Margin	-	-	-	-569.18%	-263.73%	-1110.69%	100%	20.77%
Net Margin	-	-	-	-802.66%	-421.89%	-1732.43%	-3470.05%	-12.16%
Debt / Equity	26.16x	0.00x	0.00x	0.00x	-	0.07x	0.05x	0.04x
FCF Conversion	0.87x	0.69x	0.48x	0.76x	0.97x	0.88x	0.93x	0.23x
Revenue Growth	-	-	-	-	117.19%	-66.91%	-55.77%	2752.05%

Frequently Asked Questions

Growth & Financials

Fulcrum Therapeutics, Inc. (FULC) reported $80.0M in revenue for fiscal year 2024.

Fulcrum Therapeutics, Inc. (FULC) grew revenue by 2752.0% over the past year. This is strong growth.

Fulcrum Therapeutics, Inc. (FULC) reported a net loss of $71.1M for fiscal year 2024.

Dividend & Returns

Fulcrum Therapeutics, Inc. (FULC) has a return on equity (ROE) of -4.1%. Negative ROE indicates the company is unprofitable.

Fulcrum Therapeutics, Inc. (FULC) had negative free cash flow of $60.4M in fiscal year 2024, likely due to heavy capital investments.